Segmented Biocompatible Polymer Implants for Sustained Antiviral Release
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current antiretroviral therapies for HIV require frequent and complex dosing regimens, leading to low adherence due to unpleasant side effects and lifestyle challenges, and many antiretroviral agents are not well-suited for long-acting injectable formulations due to suboptimal physicochemical properties and high dosing requirements.
Innovation Solution
Development of novel implant drug delivery systems using biocompatible polymers that encapsulate antiviral agents like 4′-ethynyl-2-fluoro-2′-deoxyadenosine, allowing for sustained release over extended periods, reducing the need for frequent dosing and improving adherence through subcutaneous implantation.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If frequent dosing regimens are used to maintain therapeutic efficacy, then viral suppression is achieved, but patient adherence deteriorates due to complexity and side effects
Solution Approach 1:
The patent segments the total monthly drug dose into multiple smaller implants (e.g., 2-4 implants per month), each delivering a fraction of the total dose. This segmentation allows for simplified administration (fewer injections) while maintaining therapeutic efficacy through distributed delivery of antiviral agents throughout the month.
Solution Approach 2:
The patent employs preliminary action by administering a loading dose of antiviral agent before the monthly implantation to achieve rapid therapeutic effect. This preliminary dosing ensures that therapeutic levels are established before the sustained-release implants begin their monthly delivery cycle, addressing the need for immediate viral suppression.
2Duration of action of moving object
If long-acting injectable formulations are developed, then dosing frequency is reduced, but injection volume and number of injections increase
Solution Approach 1:
The patent divides the total monthly drug quantity into multiple small implants, each containing a fraction of the total dose (e.g., 10-50 mg per implant). This segmentation reduces the volume of each individual injection while maintaining the total monthly dose, making administration more practical and patient-friendly.
Solution Approach 2:
The patent uses biocompatible polymer matrices (flexible shells) to encapsulate the antiviral agents in compact implant forms. These flexible polymer containers allow for small, manageable injection volumes while delivering extended-release pharmacokinetics over the monthly dosing interval.
3Ease of manufacture
If conventional drug suspensions are used, then formulation is simple, but physicochemical properties are suboptimal for long-acting delivery
Solution Approach 1:
The patent employs composite materials by combining antiviral agents with biocompatible polymer matrices (e.g., polyethylene vinyl acetate copolymer). This composite formulation enables sustained release over monthly intervals while maintaining ease of manufacture through established polymer drug delivery technologies.
Solution Approach 2:
The patent applies parameter changes by modifying the physicochemical properties of the drug delivery system through polymer encapsulation. The polymer matrix controls drug release kinetics, extending the duration of action from daily to monthly intervals while maintaining manufacturability through controlled release mechanisms.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The implant drug delivery systems provide a convenient and effective long-acting solution for HIV treatment and prevention, maintaining therapeutic plasma concentrations for several months with fewer injections, thereby enhancing patient compliance and reducing treatment-related side effects.
Implementation Method 1
The implant drug delivery systems comprise a polymer and an antiviral agent... allowing for sustained release over extended periods
Data Source
AI summary
This invention relates to novel implant drug delivery systems for long-acting delivery of antiviral drugs. These compositions are useful for the treatment or prevention of human immunodeficiency virus (HIV) infection.